Featured Stories
One Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of malignant cells throughout the body that ends up killing the majority of cancer patients.
The Case For Agile Innovation In Health Care
In a recent Bain & Company survey, nearly 80% of health care executives said they needed to be more agile. Yet more than half said they were not familiar with formal agile methodologies and tools, and were not using them in their companies.
In Vivo’s Quick Guide To Gene Therapy
Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.
Latest News
Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development
Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention
Recent Issues
Growth Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Growth
PureTech’s Problem-Solving Skills Target The BIG Picture
PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.
MorphoSys: A European Champion Crossing The Biopharma Rubicon
The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.
European Companies Are Now Being ‘Properly Funded’
In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared to the $686m companies raised in 2018 overall. Silicon Valley Bank expects the European sector to be in “rude health” for the next two to three years at least, when it comes to accessing VC cash.
Innovation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Innovation
C-Suite Snippets: Open Data And Innovation
In case you missed it: catch up with snippets from interviews published by In Vivo this month.
Why Reusable Data Matters For Future Of Pharma
Castor, a cloud-based data solution, is enabling researchers to effectively capture and integrate data from any source. CEO and founder of the company, Derk Arts, spoke to In Vivo about the importance of cohesive data for the future use of artificial intelligence in biopharma.
Coordinated Open Data Will Drive Next-Level Health Research
Experts from a European data sharing initiative talk to In Vivo about the importance of coordinated computational biology efforts for the future of life sciences innovation and the effective use of artificial intelligence.
Leadership Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Leadership
Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
Corporate Affairs: Biopharma’s First Line Of Defense Against Scrutiny
Amgen’s Judy Gawlik Brown is using her finance and consumer health background to make the big biotech’s message more authentic and accessible – a brisk reset against today’s disconnected world of alternative facts.
GSK's Hal Barron On R&D Progress At Two-Year Mark
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
From The Archives
How To Make Your Drug Launch A Success
Recently launched drugs aren't meeting sales expectations and that's bad news for an industry whose revenues come from new products. Bain & Company surveyed senior launch executives to find the factors that lead to a successful launch.
MedTech Europe's Brexit Challenge: Don't Forget The Kid In The EU Divorce
The UK continues to press for favorable trading and regulatory conditions with the EU in its Brexit planning. But EU negotiators seem likely to play it by the book, with no favors shown. The medtech industry watched as the EU withdrawal agreement was approved by the EU27 at the March 2018 Euro Summit. Some weeks prior to that, MedTech Europe chief executive Serge Bernasconi told In Vivo of his fears for EU medtech if the industry was too slow in preparing for UK withdrawal.
Market Access Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
Fully-Connected Data Infrastructure Offering Will Support Individualized Cancer Therapies
A new digital ecosphere to support the efficient delivery of individualized cancer therapies to patients has been released by data and information management company EY. It is an open source framework that can be accessed by all stakeholders in the care delivery chain.
C-Suite Snippets: Planning For The Future Cancer Market
In case you missed it: catch up with snippets from interviews published by In Vivo this week.
Get The Most Out Of Your Marketing Research
Esin Izat, a pharmaceutical marketing research expert, talks to In Vivo about how smaller companies can better utilize pre-launch marketing research and how approaches are changing to reflect new customer profiles and advances in technology.
Market Intelligence Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Intelligence
Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
Deals In Depth: August 2019
Celgene was involved in the two largest alliances of August: one to divest a product to satisfy regulatory conditions of its acquisition by Bristol-Myers Squibb and the other to develop adoptive cell therapies. There was continued acquisition activity in the CDMO market as Cambrex was bought out by investment firm Permira. Biopharma and device funding were both down.
Can Novartis Reclaim Pioneering Role In Transplantation?
Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.